A Study of Emibetuzumab in Non Small Cell Lung Cancer (NSCLC) Participants

Inclusion Criteria:

Diagnosis of metastatic Stage IV NSCLC
At least 1 measurable extra-central nervous system (CNS) lesion
Documented radiographic progression while on continuous treatment with erlotinib monotherapy
Objective clinical benefit from erlotinib treatment as defined by either documented partial or complete response or stable disease ≥6 months or, if most recent erlotinib treatment has been initiated based on documented epidermal growth factor receptor mutation (EGFRmt) status, at least 12 weeks stable disease
Determined to be MET diagnostic positive (+)
Availability of a tumor sample post-erlotinib progression
Eastern Cooperative Oncology Group (ECOG) performance status ≤2
Have adequate organ function

Exclusion Criteria:

Are currently enrolled in, or discontinued within the last 30 days from, a clinical trial involving an investigational product or non-approved use of a drug or device
Have previously been treated with LY2875358 or any other MET-targeting experimental therapeutic
Have a serious concomitant systemic disorder or significant cardiac disease
Have interstitial pneumonia or interstitial fibrosis of the lung or have pleural effusion, pericardial fluids or ascites, requiring drainage every other week or more frequently
Have a history of another malignancy except for basal or squamous cell skin cancer and/or in situ carcinoma of the cervix, or other solid tumors treated curatively and without evidence of recurrence for at least 3 years prior to the study
Have major surgery less than 2 weeks prior initiation of study treatment therapy
Pregnant or lactating women
Have symptomatic CNS metastasis